Skip to main content
TDSPHARM Co., Ltd. logo

TDSPHARM Co., Ltd. — Investor Relations & Filings

Ticker · 464280 ISIN · KR7464280007 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2025-01-09 Major Shareholding Noti…
Country KR South Korea
Listing KO 464280

About TDSPHARM Co., Ltd.

http://tdspharm.gobizkorea.com/

TDSPHARM Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Transdermal Drug Delivery Systems (TDDS), where active ingredients are absorbed through the skin. The company focuses on creating safe and effective medicinal products through dedicated R&D efforts. Its product portfolio includes a variety of TDDS-based items such as medical cataplasmas, plasters, and patches for applications like pain relief and antibiotic delivery. In addition to its core pharmaceutical business, TDSPHARM also develops and manufactures Over-The-Counter (OTC) medicines and cosmetic products, aiming to provide a wide selection of accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the acquisition of shares by Korea Securities Finance Corp in TDS Pharm. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2025-01-09 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a formal notice regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting (AGM). It is a standard regulatory announcement regarding corporate governance and shareholder rights, which does not fit into specific categories like dividend announcements or financial reports. As it is a general regulatory notification regarding meeting preparation, it falls under the RNS category.
2024-12-13 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement regarding the determination of a record date for shareholder register closure for the purpose of dividend distribution. It specifies the record date (2024-12-31) and the purpose (determining shareholders for the 23rd fiscal year dividend). While it relates to dividends, it is not the final declaration of the dividend amount itself, but rather a procedural notice regarding the record date. Given the options, this falls under the category of regulatory announcements regarding corporate actions, and since it is a specific regulatory filing regarding shareholder rights and dividend procedures, it fits best under RNS (Regulatory Filings) as it is a standard corporate disclosure.
2024-12-13 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'TDS PHARM' covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
[기재정정]분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'TDS PHARM Co., Ltd.' (주식회사 티디에스팜). It includes detailed financial data, management discussions, and operational information for the third quarter of 2024. It is not an announcement of a report, but the report itself, containing substantive financial statements and analysis. Therefore, it is classified as an Interim/Quarterly Report. 9M 2024
2024-11-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease in holdings) by a major shareholder (Brand K Youth Creation Technology Finance Private Equity Fund and its special related parties) in the company 'TDS Pharm'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-09-30 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.